Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
In the register
The register attaches this trial to Bimatoprost (scalp) (AbbVie), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1
- Sponsor
- Allergan
- Participants (registry)
- 42
- Start
- October 2010
- Primary completion
- January 2011
- Study completion
- February 2011
- Last registry update
- August 2013
- Countries
- United States
Conditions studied: Alopecia, Alopecia, Androgenetic, Baldness
Interventions: bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
Other trials of Bimatoprost (scalp)
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.